Group items tagged

The UK Government is investing £100 million to accelerate the use of AI in life sciences and healthcare under a new mission. UK Prime Minister Rishi Sunak announced the AI Life Sciences Accelerator Mission in his speech last week. The new initiative will capitalise on the UK's unique strengths in securing "health data and cutting-edge AI." It will also help to identify those at risk of "dementia" and will ensure that patients participate in the trials at the right time to develop new treatments effectively. Henceforth, it will provide us with better data on how well new therapies work. Sunak said: "AI can help us solve some of the greatest social challenges of our time. AI could help find novel dementia treatments or develop vaccines for cancer."

The Pharmacists Defence Association (PDA) has welcomed the government's action of publishing 'AI Regulation White Paper' which will regulate the artificial intelligence (AI) system used in pharmacy on Wednesday (29 March). The Association had raised concerns about the risk of patient harm due to inappropriate use of so-called AI to include that seen in some of the pharmacy systems undertaking clinical checks. For some time, it has been receiving concerns from practicing pharmacists describing examples of the potentially detrimental impact of automation and online pharmacy provision on patient safety and pharmacy practice. As a result, it raised these concerns with regulators, Chief Pharmaceutical Officers, and parliamentarians in all four nations of the UK to urge action. It said: "This is required not only to protect patients, but also the frontline pharmacists who could be blamed for potential harm caused by inappropriate use of so called 'AI' systems implemented by their employer." The PDA therefore, welcomes the announcement from the UK government that they intend to strengthen regulation of such technology, empowering existing regulators to come up with tailored, context-specific approaches that suit the way AI is actually being used in their sectors; this will include pharmacy.

The Department of Health and Social Care (DHSC) made a recent announcement that the Incubator for Artificial Intelligence (i.AI) and NHS England (NHSE) have joined forces in a groundbreaking move by signing a Collaboration Charter on AI. This pivotal partnership aims to equip the NHS workforce with the tools and resources to leverage AI technology for enhancing patient care, improving staff experience, and driving operational efficiency. The Charter, endorsed by Minister Burghart, Parliamentary Secretary for the Cabinet Office, and Lord Markham, Parliamentary Under Secretary of State at the DHSC, signifies an important step towards integrating AI into the fabric of the NHS. Under this collaboration, the i.AI team, comprising elite technical experts within the government, will identify opportunities where AI technology can be deployed responsibly to support the NHS. This initiative is expected to streamline processes, optimize resource allocation, and ultimately enhance patient outcomes.

The World Health Organization called for caution on Tuesday (May 16) in using artificial intelligence for public healthcare, saying data used by AI to reach decisions could be biased or misused. The WHO said it was enthusiastic about the potential of AI but had concerns over how it will be used to improve access to health information, as a decision-support tool and to improve diagnostic care. The WHO said in a statement the data used to train AI may be biased and generate misleading or inaccurate information and the models can be misused to generate disinformation. It was "imperative" to assess the risks of using generated large language model tools (LLMs), like ChatGPT, to protect and promote human wellbeing and protect public health, the U.N. health body said.

The National Health Service (NHS) is embracing new technology and innovations like artificial intelligence (AI) to reduce the number of missed hospital appointments and improve waiting times for elective care. Following a successful pilot in Mid and South Essex NHS Foundation Trust, the health service is set to roll out AI software to 10 more trusts across England in the coming months. The software, developed by Deep Medical in collaboration with a frontline worker and NHS clinical fellow, helps reduce the number of missed appointments by offering patients convenient time slots and backup booking options. Since the AI programme was piloted six months ago, Mid and South Essex NHS Foundation Trust has seen a 30 per cent fall in non-attendances. During the pilot period, a total of 377 did not attends (DNAs) were prevented and an additional 1,910 patients were attended.

NHS England is rolling out a range of tech and data solutions, including an artificial intelligence (AI) system, across the health service to tackle winter pressures. The AI system will be used to identify patients at risk of hospital admission so community NHS teams can get to them first and reduce pressures on A&E departments. On a trial basis, four GP practices in Somerset have started using the innovative technology which can highlight registered patients with complex health needs. Health coaches, nurses, or GPs will then reach out to the people most at risk, and provide them with a range of preventive care such as monitoring, food parcels, cleaning, shopping, as well as escalating care to specialist doctors.

Artificial intelligence (AI) in healthcare is the use of algorithms and software. its applications in healthcare and even its definition.

Artificial Intelligence, AI, AI in HealthCare, Artificial Intelligence In Healthcare, Insights Care, Best HealthCare Magazine

Artificial intelligence (AI) in healthcare is the use of algorithms and software. its applications in healthcare and even its definition.

Technology is evolving every moment, and the medical world is moving alongside with this. There is hardly anyone of us who have seen an Artificial Intelligence (AI) system in the chamber of our favorite physician. Even though we are unaware of the medical industry and the influence of artificial intelligence on it, AI is silently doing its job. It is not only looking at the biometrics, keeping track and combining through millions of past medical histories but also going through the medical research papers to make predictions about the patient's' health.

AI is silently doing its job. It is not only looking at the biometrics, keeping track and combining through millions of past medical histories but also going through the medical research papers to make predictions about the patient's' health. AI disruption has begun, and it is soon going to replace the all traditional medical systems with more precision, accuracy and efficiency.

A research team led by the University of Strathclyde in the UK has developed an artificial intelligence (AI)-based blood test for the diagnosis of brain cancer.

A University College London team of researchers has developed an artificial intelligence (AI) programme that can identify minute brain anomalies that lead to epileptic seizures. The algorithm, used in the Multicentre Epilepsy Lesion Detection project (MELD) and which reports locations of abnormalities in cases of drug-resistant focal cortical dysplasia (FCD) - a major cause of epilepsy - was developed by a multinational team who used more than 1,000 patient MRI scans from 22 international epilepsy centres. Brain regions known as FCDs have evolved improperly and frequently lead to drug-resistant epilepsy. Surgery is usually used to treat it, however, finding the lesions on an MRI is a constant problem for doctors because MRI scans for FCDs can appear normal. The scientists employed about 300,000 places throughout the brain to quantify cortical properties from the MRI scans, such as how thick or folded the cortex/brain surface was.

Saurabh Satija, the Co-founder of CureAssist is a serial entrepreneur & hit upon the idea while working with his last startup - HealthSocho. This company solved availability for alternate medicines, where he kept getting requests from users to recommend products for specific symptoms. "Since it was alternate medicine (Ayurveda, Nutraceuticals, etc.) people thought it was ok to self-medicate on the basis of symptoms." asserts Saurabh. He would consistently request HealthSocho users to visit doctors to understand what their symptom entails and why they should not self-medicate. While some patients would ignore the request, others would talk about geographical constraints and quality of doctors available in their locality.

The future of healthcare lies in embracing technology to keep patients healthy at home, exactly where a company called Healthymize is positioned.

The UK government has pledged £133m to healthcare innovation funding, which will help boost the country's innovations in medical imaging and artificial intelligence (AI), among other areas.

Glenmark, a multinational pharmaceutical company, has partnered with AI data-driven supply chain management platform 7bridges. Initially focusing on their European business, where they have operations in 15 markets, the supply chain and logistics function is a big focus area for this cost reduction. The partnership with 7bridges will allow Glenmark to baseline their supply chain data giving them visibility of data, cost and service performance across their network of logistics service providers. This exercise will identify areas where invoices from their logistics service providers are being incorrectly or overcharged. With automatic dispute raising, savings will be quickly achieved. The platform will then enable Glenmark to benchmark their data, so they can compare the performance and cost of their LSPs to the wider industry. With Glenmark's global vision to emerge as a leading integrated research-based global pharmaceutical company, this investment in their supply chain will be integral to achieving this. The next step in the partnership will be to run simulations to optimise road freight services and 3PL operations, with the aim to then roll out globally.

Reacting to recommendations from a UK-first independent review, the Department of Health and Social Care (DHSC) has outlined action to tackle potential bias in the design and use of medical devices. Professor Dame Margaret Whitehead, professor of public health at the University of Liverpool, was appointed to lead the review, which focused on three areas - optical devices such as pulse oximeters, AI-enabled devices, and polygenic risk scores (PRS) in genomics. The DHSC commissioned the medical devices review after concerns were raised that pulse oximeters - widely used during the COVID-19 pandemic to monitor blood oxygen levels - were not as accurate for patients with darker skin tones. There were worries that this could cause delays in treatment if dangerously low oxygen levels in such patients were missed. However, no evidence was found from NHS studies indicating that this differing performance had an impact on patient care. Accepting the report's conclusions, the DHSC has committed to several actions, such as ensuring the safe use of pulse oximeter devices across a range of skin tones within the NHS and eliminating racial bias from data sets employed in clinical studies.

Cancer Research UK has announced a £56m research network to transform the UK into a global hub for radiotherapy study. By leveraging the use of the latest techniques, such as FLASH radiotherapy and artificial intelligence (AI), the network aims to accelerate the development of advanced radiotherapy.